Medical Pharmaceutical Supply – Ephedrine Sulfate Injection

The contract involves the supply of four units of Ephedrine Sulfate Injection, each containing ten single-dose vials of 50 mg per 10 mL (5 mg/mL concentration), totaling 40 vials. All products must strictly comply with FDA regulations, current Good Manufacturing Practices (cGMP), and Department of Defense Logistics Agency requirements for shelf-life and labeling to ensure safety, efficacy, and regulatory alignment. The pharmaceutical supply is intended for military medical use under the Medical Supply Chain Pharm FSA, a division of the Department of Defense, and is governed as a subcontract under NAICS code 325412, which pertains to pharmaceutical and medicinal preparation manufacturing. The solicitation was posted on May 8, 2026, with a firm response deadline of May 15, 2026, requiring all proposals to meet the specified technical and regulatory criteria within this narrow window. The place of performance and point of contact details are not provided, but all deliveries must adhere to the DLA’s logistical and quality assurance standards, with full traceability and documentation required for each unit.